WBB Securities started coverage on shares of Caladrius Biosciences (NASDAQ:CLBS) in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a speculative buy rating and a $6.75 target price on the biotechnology company’s stock.
Other equities research analysts have also issued reports about the stock. Chardan Capital reissued a buy rating and set a $6.00 target price on shares of Caladrius Biosciences in a report on Sunday, May 12th. ValuEngine lowered shares of Caladrius Biosciences from a buy rating to a hold rating in a research note on Wednesday, May 1st. Zacks Investment Research downgraded shares of Caladrius Biosciences from a buy rating to a hold rating in a report on Monday, February 11th. HC Wainwright restated a buy rating and set a $18.50 price objective on shares of Caladrius Biosciences in a report on Thursday, January 24th. Finally, Dawson James restated a buy rating on shares of Caladrius Biosciences in a report on Wednesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Caladrius Biosciences has a consensus rating of Buy and a consensus target price of $9.25.
CLBS remained flat at $$3.10 during trading on Tuesday. 180 shares of the company’s stock were exchanged, compared to its average volume of 28,743. Caladrius Biosciences has a 52-week low of $2.77 and a 52-week high of $11.65.
Caladrius Biosciences (NASDAQ:CLBS) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.05). On average, equities analysts predict that Caladrius Biosciences will post -1.65 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its stake in Caladrius Biosciences by 42.9% in the 3rd quarter. Renaissance Technologies LLC now owns 280,864 shares of the biotechnology company’s stock worth $1,657,000 after purchasing an additional 84,301 shares during the period. Vanguard Group Inc boosted its stake in Caladrius Biosciences by 2.9% in the 3rd quarter. Vanguard Group Inc now owns 202,568 shares of the biotechnology company’s stock worth $1,196,000 after purchasing an additional 5,700 shares during the period. Wesbanco Bank Inc. bought a new position in Caladrius Biosciences in the 1st quarter worth approximately $36,000. Morgan Stanley boosted its stake in Caladrius Biosciences by 218.6% in the 1st quarter. Morgan Stanley now owns 6,996 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 4,800 shares during the period. Finally, Summit Trail Advisors LLC bought a new position in Caladrius Biosciences in the 1st quarter worth approximately $64,000. Hedge funds and other institutional investors own 7.10% of the company’s stock.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Recommended Story: Discount Rate
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.